PERSPECTA

News from every angle

Back to headlines

Roivant Anticipates FDA Approval for New Skin Disease Drug

Roivant Chief Executive Officer Matt Gline expects the FDA to approve the launch of a new drug designed to combat a debilitating skin disease, with plans for it to be on the market by September.

6 Aug, 15:37 — 6 Aug, 15:37
PostShare